Jennie W. Taylor

Assistant Professor
Division of Neuro-Oncology UCSF

I am an Assistant Professor in Neurology and Neurological Surgery in the Division of Neuro-Oncology at the University of California, San Francisco. I am an active clinician treating adults with primary brain tumors, as well as a researcher with interests in understanding and improving the cognitive outcomes of patients with brain tumors and their caregivers. My research also involves developing new treatment strategies, innovative imaging techniques, and comprehensive tumor analyses for patients with brain tumors.

Disclosure: Nothing to disclose

Presentation(s):

• QOLP-09 - Impact of glioblastoma (GBM) patients’ clinical and treatment characteristics on caregiver burden and quality of life (QoL)

  Friday, November 22
  2:45 PM – 2:50 PM

• QOLP-25 - Critical elements of neuro-oncology caregiver support.

  Friday, November 22
  2:50 PM – 2:55 PM

• ACTR-66 - A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent IDH1 mutant, low-grade glioma: Updated results

  Friday, November 22
  2:50 PM – 2:55 PM

• E-Talks: Group 1: Health Outcomes/Neurological Complications of Cancer and Cancer Therapy/Quality of Life/Radiotherapy/Surgical Therapy/CNS Metastases

  Friday, November 22
  7:30 PM – 8:30 PM

• QOLP-20 - Impact of glioblastoma on patient-reported symptom burden and physical activity assessed by conventional instruments and a novel device–based technology

  Friday, November 22
  7:30 PM – 9:30 PM

• ACTR-42 - PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients with Supratentorial Low-Grade Glioma [NCT NCT02023905]

  Friday, November 22
  7:30 PM – 9:30 PM

• PATH-38 - Rosette-forming glioneuronal tumor is defined by FGFR1 activating alterations with frequent accompanying PI3K and MAPK pathway mutations

  Friday, November 22
  7:30 PM – 9:30 PM

• RTHP-33 - A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma

  Saturday, November 23
  5:00 PM – 7:00 PM

• QOLP-31 - Assessing the impact of glioblastoma on work productivity in patients and their caregivers

  Saturday, November 23
  5:00 PM – 7:00 PM

• ACTR-35 - A study of race and socioeconomic status impacting therapeutic clinical trial enrollment in adult gliomas patients

  Saturday, November 23
  5:00 PM – 7:00 PM

• QOLP-13 - Impact of cannabis use on quality of life in patients with central nervous system tumors

  Saturday, November 23
  5:00 PM – 7:00 PM

• ATIM-37 - Phase II, open-label, single arm, multicenter study of avelumab with hypofractionated radiation (HFRT) for adult patients with secondarily transformed IDH-mutant glioblastoma (GBM)

  Saturday, November 23
  5:00 PM – 7:00 PM

• Cognitive Outcomes from Glioma Trials

  Sunday, November 24
  7:20 AM – 7:40 AM

• IMMU-11 - Spatiotemporal immunogenomic analysis of the T-cell repertoire in IDH-mutant lower grade gliomas

  Sunday, November 24
  10:50 AM – 11:00 AM

• PATH-66 - The genomic landscape of spinal cord ependymoma

  Sunday, November 24
  11:20 AM – 11:30 AM